drugset
drugset / Trial / NCT03554174

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174 ↗

Phase 1 Active not recruiting 18 enrolled Yale University Heffter Research Institute · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.

Timeline

Start
2018-02-27
Primary completion
2021-07-08
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 0.1 mg/kg —
Subject Psilocybin Other / unclassified 0.3 mg/kg —

Indications

major depressive disorder